- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03690427
The Cardiovascular Effects of Electronic Hookah Vaping
Investigating the Cardiovascular Toxicity of Exposure to Electronic Hookah Smoking
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095-8361
- University of California, Los Angeles
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 21-39 years old hookah smokers: smoked hookah >12x in last 12 months
- no history of illicit drugs or marijuana
- no evidence of cardiopulmonary disease by history/ physical
- no diabetes: fasting blood glucose <100 mg/dl
- BP<140/90mmHg
- resting HR<100 bpm
- BMI<30kg•m2
- no prescription medication
Exclusion Criteria:
- exhaled CO>10 ppm (smoking non-abstinence)
- positive pregnancy test
- psychiatric illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Traditional Charcoal-Heated Hookah followed by Electronic Hookah
Participants were invited to smoke a 30-minute traditional charcoal-heated hookah-smoking session, followed by a 30-minute electronic hookah vaping session. To mitigate the impact of carryover effects, the two sessions were separated by a minimum of 7-days. |
Charcoal-heated hookah smoking
Other Names:
Electronic hookah bowl inhalation
|
|
Experimental: Electronic followed by Traditional Charcoal-Heated Hookah
Participants were invited to vape a 30-minute electronic hookah session, followed by a 30-minute traditional charcoal-heated hookah smoking session. To mitigate the impact of carryover effects, the two sessions were separated by a minimum of 7-days. |
Charcoal-heated hookah smoking
Other Names:
Electronic hookah bowl inhalation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Flow-Mediated Dilation (FMD)
Time Frame: Pre- and post- the 30-minute smoking or vaping exposure sessions
|
Using ultrasound, FMD of the brachial artery induced by reactive hyperemia, was used to measure endothelium-dependent vasodilator function.
Baseline diameter and velocity were recorded for 45 seconds and resumed 30 seconds before cuff deflation and continuously for 2 minutes after deflation to obtain true peak vasodilatory response.
|
Pre- and post- the 30-minute smoking or vaping exposure sessions
|
|
Carotid-Femoral Pulse Wave Velocity (Cf-PWV)
Time Frame: Pre- and post- the 30-minute smoking or vaping exposure sessions
|
Using applanation tonometry, cf-PWV was used to measure central arterial stiffness.
|
Pre- and post- the 30-minute smoking or vaping exposure sessions
|
|
HDL Oxidant Index (HOI)
Time Frame: Pre- and post- the 30-minute smoking or vaping exposure sessions
|
Capacity was determined as the ability of HDL to inhibit LDL-induced oxidation of dihydrodichlorofluorescein into the fluorescent dichlorofluorescein.
Capacity was expressed as an HDL oxidative index, determined by the ratio of dichlorofluorescein fluorescence in the presence and absence of HDL.
An index of < 1.0 denotes protective antioxidant HDL, whereas an index of > 1.0 indicates pro-oxidant HDL.
|
Pre- and post- the 30-minute smoking or vaping exposure sessions
|
|
Paraoxonase-1 (PON-1) Activity
Time Frame: Pre- and post- the 30-minute smoking or vaping exposure sessions
|
PON-1 activity was determined by the ability of PON-1, associated with HDL, to hydrolyze paraoxon substrate. The hydrolysis of paraoxon (diethyl-p-nitrophenyl phosphate) to p-nitrophenol by PON-1 was determined by incubating 5 mL of plasma with 1.0 mM paraoxon in 100 mM tris-HCl buffer (pH, 8.5). Unit of Measure: expressed as micromoles of p-nitrophenol formed per minute for every 1 mL plasma. |
Pre- and post- the 30-minute smoking or vaping exposure sessions
|
|
Arylesterase Activity
Time Frame: Pre- and post- the 30-minute smoking or vaping exposure sessions.
|
Arylesterase activity (lipid peroxidation biomarker) was determined by the rate of hydrolysis of phenyl acetate to phenol. Briefly, 4 mL plasma was incubated with 3.5 mM phenyl acetate in 9 mM Tris-HCl buffer (pH, 8.0) containing 0.9 mM CaCl2 at RT. The kinetics of phenol formation were determined by recording the absorbance at 270 nm every 15 s for 2 min. Unit of Measure: nanomoles of product formed per minute per milliliter of plasma. |
Pre- and post- the 30-minute smoking or vaping exposure sessions.
|
|
High-sensitivity C-reactive Protein (Hs-CRP) Levels
Time Frame: Pre- and post- the 30-minute smoking or vaping exposure sessions
|
Plasma hs-CRP (inflammatory biomarker)
|
Pre- and post- the 30-minute smoking or vaping exposure sessions
|
|
Tumor Necrosis Factor-α (TNFα) Concentrations
Time Frame: Pre- and post- the 30-minute smoking or vaping exposure sessions
|
Plasma TNFα (inflammatory biomarker)
|
Pre- and post- the 30-minute smoking or vaping exposure sessions
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Flow-Mediated Dilation (FMD)
Time Frame: Effect of FMD with e-hookah vaping examined after pretreatment of intravenous infusion of antioxidant ascorbic acid (administered over 60 minutes at 0.5 mL min-1)
|
Using ultrasound, FMD of the brachial artery, induced by reactive hyperemia, was used to measure endothelium-dependent vasodilator function after intravenous infusion of antioxidant ascorbic acid.
Infusion of antioxidant ascorbic acid was done before the e-hookah vaping session.
|
Effect of FMD with e-hookah vaping examined after pretreatment of intravenous infusion of antioxidant ascorbic acid (administered over 60 minutes at 0.5 mL min-1)
|
|
Endothelium-independent Vasodilator Function (Control Test for Endothelium-dependent Vasodilator Function)
Time Frame: Pre- and post- sublingual administration of nitroglycerin (0.15 mg), which was administrated before and after e-hookah vaping.
|
As a control test for the assessment of endothelium-dependent vasodilator function, using ultrasound the brachial artery, endothelium-independent dilatation was assessed by administering sublingual nitroglycerin.
This measure was assessed 10 minutes after FMD testing.
Ultrasound images were recorded continuously for a total of 10 minutes
|
Pre- and post- sublingual administration of nitroglycerin (0.15 mg), which was administrated before and after e-hookah vaping.
|
|
Augmentation Index (AI)
Time Frame: Pre- and post- the 30-minute smoking or vaping exposure sessions
|
AI was used to measure central stiffness.
It was calculated as the ratio of augmentation pressure (difference between the second and first systolic peaks of the aortic pressure waveform) and pulse pressure expressed as a percentage.
|
Pre- and post- the 30-minute smoking or vaping exposure sessions
|
|
Interleukin 6 (IL-6) Levels
Time Frame: A change between two points is reported below (e.g., value at post-exposure session minus value at pre-exposure session).
|
Plasma IL-6 (inflammatory biomarker).
|
A change between two points is reported below (e.g., value at post-exposure session minus value at pre-exposure session).
|
|
Interleukin 10 (IL-10) Levels
Time Frame: A change between two points is reported below (e.g., value at post-exposure session minus value at pre-exposure session).
|
Serum IL-10 (anti-inflammatory biomarker)
|
A change between two points is reported below (e.g., value at post-exposure session minus value at pre-exposure session).
|
|
Nicotine Levels
Time Frame: Pre- and post- the 30-minute smoking or vaping exposure sessions
|
Plasma nicotine levels (smoking or vaping exposure biomarker)
|
Pre- and post- the 30-minute smoking or vaping exposure sessions
|
|
Carbon Monoxide (CO) Levels
Time Frame: Pre- and post- the 30-minute smoking or vaping exposure sessions
|
Exhaled CO levels (smoking or vaping exposure biomarker)
|
Pre- and post- the 30-minute smoking or vaping exposure sessions
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Rezk-Hanna M, Gupta R, Nettle CO, Dobrin D, Cheng CW, Means A, Brecht ML, Tashkin DP, Araujo JA. Differential Effects of Electronic Hookah Vaping and Traditional Combustible Hookah Smoking on Oxidation, Inflammation, and Arterial Stiffness. Chest. 2022 Jan;161(1):208-218. doi: 10.1016/j.chest.2021.07.027. Epub 2021 Jul 21.
- Rezk-Hanna M, Seals DR, Rossman MJ, Gupta R, Nettle CO, Means A, Dobrin D, Cheng CW, Brecht ML, Mosenifar Z, Araujo JA, Benowitz NL. Ascorbic Acid Prevents Vascular Endothelial Dysfunction Induced by Electronic Hookah (Waterpipe) Vaping. J Am Heart Assoc. 2021 Feb;10(5):e019271. doi: 10.1161/JAHA.120.019271. Epub 2021 Feb 20.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R21HL145002-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Center for Research and Innovation Viña Concha...Universidad Católica del MauleNot yet recruitingInflammaging | Antioxidant Status, Inflammation | Inflammation Biomarkers | Antioxidant Capabilities | Cardiometabolic Health IndicatorsChile
-
University of NebraskaNot yet recruiting
-
Central Hospital, Nancy, FranceRecruiting
-
Oral Science International Inc.AdvarraNot yet recruiting
-
University of NebraskaCompletedPeriodontal InflammationUnited States
-
University of California, DavisCompleted
-
Università degli Studi di BresciaCompletedVitreous Inflammation
Clinical Trials on Traditional hookah smoking
-
Cedars-Sinai Medical CenterUniversity of California, Los Angeles; University of California, San FranciscoTerminated
-
Cedars-Sinai Medical CenterCompleted
-
NYU Langone HealthCompleted
-
Georgetown UniversityNational Cancer Institute (NCI)CompletedHookah Tobacco SmokingUnited States
-
Duke Kunshan UniversityCompletedSmoking Cessation | Lifestyle, HealthyChina
-
Georgetown UniversityNational Cancer Institute (NCI)CompletedHookah SmokingUnited States
-
University of California, San FranciscoTobacco Related Disease Research ProgramCompleted
-
University of California, Los AngelesActive, not recruitingVascular Stiffness | Vaping | Hookah Smoking | Secondhand AerosolUnited States
-
University of California, Los AngelesTobacco Related Disease Research ProgramCompleted
-
Cedars-Sinai Medical CenterTerminatedNicotine-free Hookah SmokingUnited States